If we accept this result as real, it means that the recent increase in the incidence of APN in Korea has emerged as a new serious problem. For what reason did this new problem arise?
However, these big data have a fundamental limitation in that they are not collected for the purpose of clinical research from the beginning. Moreover, it does not contain the private information of the patients and is limited to the 5-year deadline. Therefore, there is a problem with accuracy and validity in analyzing these vast amounts of data. 1 These data are inherently entered for insurance claim purposes and cannot guarantee the accuracy of the diagnosis. 2 That is, there is a high risk that the claimed diagnosis and the actual diagnosis could be different from each other, resulting in an unexpected result. Overestimation or underestimation of a disease can occur.
In this issue, Kim et al. 3 analyzed the status of acute pyelonephritis (APN) in Korea based on the HIRA data from 2010 to 2014. The authors' conclusion shows a very surprising result. The mean incidence for 5 years is 39.1/10,000. And the incidence, which was 35.6/10,000 in 2010, increased significantly to 43.8/10,000 in 2014. In the late 1990s, its incidence has been reported at 35.7 cases per 10,000 persons in Korea, and this figure has steadily maintained without any significant change until 2010, and has increased rapidly in just five years. 4 The authors are suspicious of the increased antibiotic resistance of microorganisms causing APN. In fact, the antibiotic susceptibility of Escherichia coli isolated from patients with APN to ciprofloxacin and trimethoprim/sulfamethoxazole has gradually decreased. 5 The authors noted that the occurrence rate of Korean resistant strains of E. coli (ST131) increased from 19.7% in 2011 to 26.9% in 2016, assuming as a partially explainable basis for the increase in incidence of APN. Of course, this is not the evidence used directly in this study, it is only an estimate of the authors. Therefore, this assumption may be partially explained, but it cannot be a satisfactory explanation. This is one of many blunders in data analysis using big data. As mentioned at the beginning, HIRA's big data consist of diagnostics entered for the purpose of claiming. However, the patient's personal information and various test result information are missing. The diagnosis of APN is also problematic in terms of accuracy. In practice, cystitis and asymptomatic bacteriuria are also likely to be included as APNs. Therefore, there is a limit to accurately and finely describing the fact that the incidence of APN has increased. To put it bluntly, it cannot be dismissed even if one concludes that the rate of claiming the APN, not the incidence of it, has increased.
While this paper is an excellent example of getting meaningful conclusions using big data, it also shows the loopholes of big data itself. In a nutshell, big data is not a panacea yet, but a double-edged sword.
